Skip to main content

Myelodysplastic Syndrome

Breadcrumb

  1. Home

User login

  • Reset your password

December 2020

  • Synthetic retinoid shows potential for myeloid malignancies
  • Monthly azacitidine injections reduce relapse in acute myeloid leukemia and myelodysplastic syndrome
  • Food supplements improve mitochondrial respiration in myelodysplastic syndrome
  • Imetelstat curbs need for blood transfusions in myelodysplastic syndrome
  • Azacitidine shows safety but lacks effectiveness for relapse reduction in myelodysplastic syndrome and acute myeloid leukemia
  • Novel gene fusions surface more often in acute myeloid leukemia vs. myelodysplastic syndrome
  • Genetic mutation burden can predict prognosis for myelodysplastic syndrome
     

November 2020

Dr. Guillermo Montalban Bravo: Specific guidelines for the management of SARS-CoV-2 infection in patients with MDS remains of paramount importance

  • COVID-19 may be more lethal in MDS patients
  • New form of programmed cell death has cancer treatment implications
  • Genome study identifies potential treatment target for myelodysplastic syndrome patients
  • Dialysis predicts increased risk of myelodysplastic syndrome
  • Bronchoscopy remains a safe choice for most patients with malignant hematologic disorders
  • Most transfusion-dependent MDS patients report positive quality of life
  • Luspatercept shows promise as efficacy marker in MDS patients
  • Gene mutations may predict risk of vascular events in MDS